B. Gulekli ( Department of Reproductive Endocrinology and Infertility, Zekal Tahir Burak Women’s Hospital, Ankara, Turkey. )
G. Ozaksit ( Department of Reproductive Endocrinology and Infertility, Zekal Tahir Burak Women’s Hospital, Ankara, Turkey. )
N.O. Turhan ( Department of Reproductive Endocrinology and Infertility, Zekal Tahir Burak Women’s Hospital, Ankara, Turkey. )
S. Senoz ( Department of Reproductive Endocrinology and Infertility, Zekal Tahir Burak Women’s Hospital, Ankara, Turkey. )
H. Oral ( Department of Reproductive Endocrinology and Infertility, Zekal Tahir Burak Women’s Hospital, Ankara, Turkey. )
O. Gokmen ( Department of Reproductive Endocrinology and Infertility, Zekal Tahir Burak Women’s Hospital, Ankara, Turkey. )
Twenty patients with ultrasound diagnosed polycystic ovaries and high luteinizing hormone levels who failed to respond to clomiphene citrate were given tamoxifen to induce ovulation. Tamoxifen 20 mg daily (group 1, n=10) and 40 mg daily (group 2, n=10) was given far 5 consecutive days from the third to seventh day of the cycle. Treatment was monitored by serial ultrasound scans and assessment of serum estradial. Human charionic ganadatraphin (hCG) was administered when atleast one fallicule was >16mm and serum estradial level was >300pg/ml per fallicule. Ovulation was confirmed with detection af the follicular rupture ultrasanagraphically 2 days after hCG and midluteal progesterone levels. The ovulation rate achieved in group 2 patients was signif icantly higher (p=0.01) than group 1. Three pregnancies were achieved in group 2 patients while there was no pregnancy in group 1. The only side effect was ovarian cyst formation In one patient in group 1. As a result, tamaxifen might be a good choice for clamiphene resistant patients prior to treatment with surgery or hMG (JPMA 43: 89, 1993).
Multiple methods can be used to induce ovulation in patients with polycystic ovaries (PCO). Clomiphene Citrate (CC) is the first choice of treatment in many infertility clinics with an ovulation rate of about 80% and apregnancy rate is 40%1-3. When this agent fails to correct the situation one can choose one of the other methods which are available. The results of surgical treatments (ovarian wedge resection and laparoscopic electrodiathermy) are variable and any beneficial effect is short lived. On the other hand the medical methods for inducing the ovulation in clomiphene resistant polycystic ovarian syndrome (PCOS) patients will be human menopausal gonadotrophins (hMG or pure FSH) with or without gonadotrophin releasing hormone analogs. Before this relatively expensive choice we tried tamoxifen in patients who failed to respond CC. Tamoxifen is a potent, non-steroidal anti-estrogen. Its mechanism of action in clomiphene resistant patients is not clear.
PATIENTS AND METHODS
The study group comprised of 20 women with ultrasound diagnosed PCO as defined byAdams et al4 and elevated LH/FSH ratio, who failed to ovulate with CC 200 mg/daily atleast in their 3 subsequent cycles. Tamoxifen 20 mg daily (group 1, n= 10) and 40 mg daily (group 2, n= 10) was given for 5 consecutive days from the third to the seventh cycle day. All these women were nor- moprolactinaemic and they had no other endocrine disorder. Before beginning the treatment venous blood samples were obtained on day 3 of their cycles for determination of estradiol (E2), progesterone (P), gonadotrophins and prolactin (PRL) and a preliminary ultrasound scan was performed. Treatment was monitored by serial ultrasound scans and assessment of serum E2 levels. Ultrasound was performed on alternate days from day 10 until ovulation was occurred or it became apparent that the cycle was anovulatory. Serum E2 and P levels were also measured on the days of ultrasound scanning. Human chorionic gonadotrophin (hCG) was administered in a dosage of 10,000 IU when atleast one follicule was _ 16 mm and serum E2 level was _300 pg/ml per follicule. Ovulation was detected with follicular rupture ultrasonographically confirmed by serum B-hCG levels 20 days after proposed ovulation. Data were analyzed on a desk top computer using a statistical package (SPSS-PC). Fisher’s exact probability test and paired t-tests were used to determine statistical significance, the results were expressed as the mean± the standard error of mean (SEM).
After the first tamoxifen trial the results were analyzed. There was no significant difference between the groups regarding their age and baseline hormone levels (Table I).
Interval between the commencement of treatment and ovulation was a mean of 10.2 ± 1.0 days in group 1 and 11.1±1.2 days in group 2, which did not reach statistical significance. The results of treatment are shown in Table II.
Three singleton pregnancies were achieved in the study period. One of the three pregnant women in the study had abortion during an early period of pregnancy, the other two pregnancies are currently at an advanced stage. In one of the group 1 patients a 49x40 mm ovarian cyst was detected in her right ovary during follicular phase. This patient failed to ovulate. This was the only side effect that was recorded during the study.
This preliminary study suggests that tamoxifen may be an alternative to the treatment of clomiphene resistant patients. Furthermore, in the patients who were not clomiphene resistant Weseley et al5 report more successful results regarding ovulation and pregnancies achieved. Ovulation and pregnancy achieving efficiency of tamoxifen was also evaluated in comparison with dosage in this study. The patients who are anovulatory previously with CC responded to 40mg daily tamoxifen with a rate of 70% while women who were treated with 20 mg daily did not respond favourably. Treatment with 40mg was considered necessary in order to induce satisfactory rates of ovulation in clomiphene resistant PCOS patients. However, we were not able to show similar results with pregnancy rates but we believe that larger number of treatment cycles could possibly produce a higher pregnancy rate. On the other hand while Borenstein et al6 described their successful results without any side effect, we detected an ovarian cyst which caused anovulation in that cycle. Further investigations will be necessary in the future concerning this matter. Finally, we conclude that tamoxifen 40 mg daily might be a good choice for clomiphene resistant PCOS patients prior to treatment with surgery or hMG.
1. Lobo, R.A., Gysler. M., March, C.M., Goeblesnan, U. and Mishell, OR. Jr. Clinical and laboratocy predictors of clouniphene response. Fertil. Steril, 1982;37:168-74.
2. Rust, LA., Israel, It. and Miahell, D.R. Jr. An individualized graduated therapeutic regimen for clomiphene citrate. Am.J.Obstet.Gynecol., 1974420:785-90.
3. Hammond, M.O., Halme, J.K. and Talbert, LM. Factors affectingthe pregnancy rate in clomiphene citrate induction ofovulation. Obstet. Gynecol., 1983;62:196-202.
4. Adams, 3., PoIson, OW. and Franks, S. Prevalence of polycystic ovaries in women with snovulation and idiopathic hirsutism. Br.Med.J., 1986;293:355-59.
5. Weaeiey, AC and Meinick, H. Tamoxfen in ciomiphene resistant hypothalamic anovulation. Int.J.Fertil., 1987;32:226-28.
6. Borenstein, R., Shoam, Z., Yemini, M. et al. Tamoxifen treatmentinwomen with failure of clomiphene citrate therapy. Aust. N.Z.J. Obstet Gynaecol., 1989;29:173-75.